Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Quinocide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 11/20 | 1.00 |
| ▸ | HSP90AB1 known ✓ | P08238 | 11/20 | 1.00 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 1.00 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.61 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.61 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.61 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.61 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.61 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.61 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.61 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.61 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.61 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.61 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.61 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.61 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.61 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.61 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.61 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.61 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinocide SCHEMBL30823571 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ALDH1A1MEN1KMT2A | |
| Quinocide SCHEMBL28060369 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ALDH1A1MEN1KMT2A | |
| Quinocide SCHEMBL29720457 | 0.99 | MEN1 (1.00) | HSP90AA1HSP90AB1ALDH1A1MEN1KMT2A | |
| Quinocide SCHEMBL157174 | 0.99 | MEN1 (1.00) | HSP90AA1HSP90AB1ALDH1A1MEN1KMT2A | |
| Quinocide SCHEMBL2286358 | 0.93 | MEN1 (0.88) | HSP90AA1HSP90AB1ALDH1A1MEN1KMT2A | |
| SCHEMBL17792862 | 0.84 | HSP90AA1 (0.93) | HSP90AA1HSP90AB1ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL11410128 | 0.84 | HSP90AA1 (0.95) | HSP90AA1HSP90AB1ALDH1A1MEN1KMT2A | |
| SCHEMBL8893299 | 0.83 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ALDH1A1MEN1KMT2A | |
| Pentaquine SCHEMBL980723 | 0.83 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1ALDH1A1MEN1KMT2A | |
| Pentaquine SCHEMBL29596989 | 0.83 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | CELLECTIS SA (FR) | 2023-12-28 | — | — | US | claimed |
| EP-4251746-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | Cellectis SA (FR) | 2023-10-04 | — | — | EP | claimed |
| US-20230000893-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | UNIV EMORY (US) | 2023-01-05 | — | — | US | claimed |
| WO-2022112596-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | CELLECTIS SA (FR) | 2022-06-02 | — | — | WO | claimed |
| WO-2017165489-A1 | ANTIVIRAL AGENTS FOR TREATING ZIKA AND DENGUE VIRUS INFECTIONS | EMORY UNIVERSITY (US) | 2017-09-28 | — | — | WO | claimed |
| EP-2694086-A1 | MHC ENGAGEMENT AND CLIP MODULATION FOR THE TREATMENT OF DISEASE | The Texas A&M University System (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2012138708-A1 | MHC ENGAGEMENT AND CLIP MODULATION FOR THE TREATMENT OF DISEASE | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-10-11 | — | — | WO | claimed |
| WO-2012135632-A2 | METHODS OF TREATING A SUBJECT HAVING BEEN EXPOSED TO A CATASTROPHIC EVENT | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-10-04 | — | — | WO | claimed |
| WO-2026102297-A1 | ANTIBODY OLIGONUCLEOTIDE CONJUGATES FOR TREATING DISEASE | Fulcrum Therapeutics, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4735051-A1 | COMPOSITIONS AND METHODS OF USING PLN-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Atrium Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735602-A2 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES ABSTRACT | Atrium Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260048135-A1 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Atrium Therapeutics, Inc. | 2026-02-19 | — | — | US | disclosed |
| US-12529056-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20260014266-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | AVIDITY BIOSCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20050014785-A1 | Treatment of radiation disorders | PERLEGEN SCIENCES, INC. (US) | 2005-01-20 | — | — | US | disclosed |
| US-20040229908-A1 | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias | Greenlee, Winner and Sullivan, P.C. | 2004-11-18 | — | — | US | disclosed |
| WO-2004085402-A1 | RING-SUBSTITUTED 8-AMINOQUNOLINE DERIVATES AS ANTIMALARIAL AGENTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004050837-A2 | TREATMENT OF DNA DAMAGE RELATED DISORDERS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050842-A2 | ATM KINASE COMPOSITIONS AND METHODS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2004-06-17 | — | — | WO | disclosed |
| US-6417177-B1 | Chloroquine derivatives for the treatment of Parkinson's disease | ALPHA RESEARCH GROUP, LLC | 2002-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014785-A1 | Treatment of radiation disorders | XRCC5, XRCC6, QTRT1 | HSP90AA1 540/4885HSP90AB1 741/4885GAA 233/4885 |
| US-20260048135-A1 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | MYLK2, PRKCG, PRKAG2 | HSP90AA1 2999/4885HSP90AB1 3080/4885GAA 1067/4885 |
| US-20260014266-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | TNNC1, MYOF, MYH2 | HSP90AA1 3054/4885HSP90AB1 2744/4885GAA 2665/4885 |
| US-20230000893-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | SAMHD1, PNP, NUDT1 | HSP90AA1 3887/4885HSP90AB1 3901/4885GAA 1906/4885 |
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | ERCC4, LIG4, LIG3 | HSP90AA1 3855/4885HSP90AB1 3748/4885GAA 221/4885 |
| US-12529056-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | UPF1, MYOF, MTPN | HSP90AA1 4833/4885HSP90AB1 4752/4885GAA 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.